Mark Asset Management LP Bio N Tech Se Transaction History

Mark Asset Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $2.11 Million - $2.64 Million	-17,194 Reduced 42.86%	22,920 $2.86 Million
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $2.56 Million - $4.02 Million	-21,620 Reduced 35.02%	40,114 $6.03 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $2.99 Million - $4.52 Million	24,265 Added 64.76%	61,734 $9.21 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $6.62 Million - $12.2 Million	-52,473 Reduced 58.34%	37,469 $6.39 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $16 Million - $26.9 Million	74,073 Added 466.78%	89,942 $23.2 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $3.27 Million - $7.1 Million	15,869 New	15,869 $4.33 Million

360

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $30B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Mark Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Mark Asset Management LP with notifications on news.